Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial

<p><strong>Background:</strong></p> Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of acti...

Full description

Bibliographic Details
Main Authors:	Hundertmark, MJ, Adler, A, Antoniades, C, Coleman, R, Griffin, JL, Holman, RR, Lamlum, H, Lee, J, Massey, D, Miller, JJJJ, Milton, JE, Monga, S, Mózes, FE, Nazeer, A, Raman, B, Rider, O, Rodgers, CT, Valkovič, L, Wicks, E, Mahmod, M, Neubauer, S
Format:	Journal article
Language:	English
Published:	American Heart Association 2023

Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial

Similar Items